[Federal Register Volume 89, Number 186 (Wednesday, September 25, 2024)]
[Notices]
[Page 78321]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21859]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and/or contract proposals 
and the discussions could disclose confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications and/or contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Device Based Treatments for Substance Use Disorders.
    Date: October 30, 2024.
    Time: 10:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer, 
Scientific Review Branch, Office of Extramural Policy, National 
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 
6021, Bethesda, MD 20892, (301) 443-4577, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Analytical Service Center for Medications 
Development Program.
    Date: October 30, 2024.
    Time: 12:00 p.m. to 2:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer, 
Scientific Review Branch, Office of Extramural Policy, National 
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 
6021, Bethesda, MD 20892, (301) 827-5843, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Developing Regulated Therapeutic and Diagnostic 
Solutions for Patients Affected by Opioid and/or Stimulants Use 
Disorders.
    Date: November 7-8, 2024.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Sudhirkumar U. Yanpallewar, M.D., Scientific 
Review Officer, Scientific Review Branch, Office of Extramural 
Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet 
Avenue, MSC 6021, Bethesda, MD 20892, (301) 443-4577, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Initial 
Review Group; Medication Development Research Study Section.
    Date: November 13, 2024.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer, 
Scientific Review Branch, Office of Extramural Policy, National 
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 
6021, Bethesda, MD 20892, 301-443-4577, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

     Dated: September 19, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-21859 Filed 9-24-24; 8:45 am]
BILLING CODE 4140-01-P